Stuart Therapeutics Announces First Patient, First Visit in its Phase 3 Clinical Trial of Vezocolmitide for Dry Eye Disease
Stuart Therapeutics, Inc. ("Stuart"), a clinical stage biopharmaceutical company conducting research and development of unique extracellular matrix-targeting peptide therapeutics for ophthalmic diseases, today announced the First Patient First Visit...
United States Polycoltm Polycol Eric Schlumpf Prnewswire Stuart Therapeutics Inc Therapeutics Announces First Patient First Visit
Source: lelezard.com